Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cue Biopharma Inc (CUE)
NASDAQ:CUE
Holding CUE?
Track your performance easily
Earnings Data
Report Date
Mar 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.09Last Year’s EPS
-$0.28Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -32.67%
|Next Earnings Date:Mar 12, 2025
Earnings Call Sentiment|Neutral
The call presented several positive developments in clinical trials and strategic financial management, but also noted delays in trial launches and competitive market challenges.Company Guidance
During Cue Biopharma's Q2 2024 earnings call, the executives provided guidance on several metrics and strategic priorities. They highlighted their focus on reducing capital requirements by achieving a cash burn reduction from $40 million to $30 million annually, extending their runway to mid-2025. The company is advancing its CUE-101 and CUE-102 oncology programs, with CUE-101 showing an objective response rate of 46% and a notable 12-month overall survival rate of 90% in a combination trial with pembrolizumab. Cue-401, in collaboration with ONO Pharmaceuticals, targets autoimmune diseases, with lead candidate selection anticipated in Q1 2025. Additionally, CUE-501 is being positioned for strategic partnering, aimed at addressing B-cell-mediated autoimmune diseases. The company's approach includes leveraging strategic partnerships to optimize resource allocation and bolster cash flow through milestone payments and potential co-development agreements.CUE-101 and Pembrolizumab Combination Shows Promising Results
CUE-101 in combination with Pembrolizumab shows an objective response rate (ORR) of 46% in patients with CPS ≥ 1, compared to the historical ORR of 19% with Pembrolizumab alone. The 12-month overall survival (OS) is 90% with a median OS of 21.8 months.
Strong Performance in Low CPS Score Patients
Patients with low CPS scores (1 to 19) showed an ORR of 50% with CUE-101 and Pembrolizumab, significantly higher than the historical 15% with Pembrolizumab alone.
CUE-401 Autoimmune Program Progress
CUE-401, in collaboration with ONO Pharmaceuticals, shows promising data in generating regulatory T cells and is moving towards lead candidate selection in Q1 2025.
Financial Strategy and Extended Runway
Through strategic measures, the company's runway is extended to mid-2025 while reducing annual cash burn from $40 million to $30 million.
---
CUE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CUE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $1.50 | $1.24 | -17.33% |
| Aug 19, 2024 | $0.76 | $0.86 | +13.16% |
| May 09, 2024 | $1.92 | $1.74 | -9.37% |
| Apr 08, 2024 | $2.04 | $1.90 | -6.86% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cue Biopharma Inc (CUE) report earnings?
Cue Biopharma Inc (CUE) is schdueled to report earning on Mar 12, 2025, TBA Not Confirmed.
What is Cue Biopharma Inc (CUE) earnings time?
Cue Biopharma Inc (CUE) earnings time is at Mar 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CUE EPS forecast?
CUE EPS forecast for the fiscal quarter 2024 (Q4) is -$0.09.
---